Navigation Links
Topical treatment shown to inhibit HIV and herpes simplex virus infection

Mount Sinai School of Medicine researchers demonstrated that a gel applied in the vagina provides protection from both the human immunodeficiency virus (HIV) and the herpes simplex Virus. The study, presented at the 12th Conference on Retroviruses and Opportunistic Infections, is the first to show that a gel can retain anti-viral activity within the human vagina.

The study, which was funded by the National Institutes of Health (NIH) investigated the efficacy of PRO 2000, a topical microbicide under development by Indevus Pharmaceuticals, Inc.

"There is an urgent need for the development of safe and effective vaginal microbicides," Marla Keller, M.D., Assistant Professor of Medicine at the Mount Sinai School of Medicine and the researcher who presented the data. "While condoms offer protection against sexually transmitted infections, their effectiveness is limited because they require partner initiation or consent."

According to the United Nations' 2004 report on the global AIDS epidemic, an estimated 40 million people worldwide are living with HIV, and women account for nearly half of those infected. As stated by the World Health Organization, unprotected sex is the predominant mode of HIV transmission, and genital herpes plays a major role in the sexual spread of HIV.

The researchers conducted a prospective, randomized, double blind, placebo-controlled study among 20 HIV-infected women to assess the antiviral activity of PRO 2000 in cervicovaginal lavage (CVL) fluid collected before and one hour after administration of a single intravaginal dose of PRO 2000 gel or a matched placebo gel. CVL specimens were tested for their ability to prevent HIV and HSV infection of susceptible human cells in culture. Levels of inflammatory cytokines were also measured as markers of acute inflammation.

Analyses showed that CVL obtained after the application of PRO 2000 gel reduced both HIV and HSV infectivity by at least 1000-fold compared to C VL obtained at baseline. The effects were highly statistically significant (p<0.001). In contrast, CVL collected from placebo gel recipients showed little or no anti-viral effect. Furthermore, the researchers found similar low levels of inflammatory cytokines in CVL collected from the drug and placebo groups, indicating that PRO 2000 application did not induce an acute inflammatory response.

"An inflammatory responses could potentially increase susceptibility to HIV and limit any protective effect of microbicides." said Betsy Herold, M.D., Professor of Medicine and Chief of Pediatric Infectious Disease at Mount Sinai and the senior investigator on this study. "We are currently conducting a 14-day study to assess whether or not there is an inflammatory response after repeated applications."


Source:Mount Sinai Hospital / Mount Sinai School of Medicine

Related biology news :

1. Protein discovery could unlock the secret to better TB treatment
2. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
3. Researchers add new tool to tumor-treatment arsenal
4. Potential treatments for neurofibromatosis
5. Nanoparticles offer new hope for detection and treatment
6. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
7. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
8. New understanding of DNA repair may pave way to cancer treatments
9. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
10. Newer imaging techniques may lead to over-treatment
11. Asymptomatic HIV babies could use earlier treatment
Post Your Comments:

(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... NEW YORK , October 13, 2015 ... biotechnology acceleration and development company, has entered into a ... New York and Paris, France ... --> --> This collaborative ... a highly respected scientific advisory team as well as ...
(Date:10/13/2015)... TORONTO , Oct. 13, 2015  Generex Biotechnology ... has entered into a non-binding Letter of Intent (LOI) with ... that has developed a proprietary cooling technology designed to improve ... the United States and three million ... of 25 and 44 diagnosed as infertile.  For 42% of ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... focused ultrasound (HIFU) technologies, announced today that it received de novo clearance from ... in the U.S. for the ablation of prostate tissue. Sonablate® is the first ...
(Date:10/13/2015)... 13, 2015 the United States ... .  PRCC represents about 14% of all new cases of kidney ... Canada and Europe . ...   --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) ... and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment in a global ...
Breaking Biology Technology: